Circassia Group Plc (82C) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Circassia Group Plc (82C) has a cash flow conversion efficiency ratio of 0.031x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.50 Million) by net assets (€80.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Circassia Group Plc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Circassia Group Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Circassia Group Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Circassia Group Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hudson Technologies Inc
NASDAQ:HDSN
|
0.033x |
|
Suzhou Iron Technology Co. Ltd. A
SHG:688329
|
0.051x |
|
China General Plastics Corp
TW:1305
|
0.032x |
|
Sampo Corp
TW:1604
|
0.059x |
|
Jiin Yeeh Ding Enterprise Co Ltd
TWO:8390
|
0.035x |
|
Kangstem Biotech Co. Ltd
KQ:217730
|
-0.059x |
|
Oncoclinicas do Brasil
SA:ONCO3
|
0.127x |
|
RMR Group Inc
NASDAQ:RMR
|
0.026x |
Annual Cash Flow Conversion Efficiency for Circassia Group Plc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Circassia Group Plc from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €67.60 Million | €15.40 Million | 0.228x | -21.19% |
| 2024-12-31 | €59.50 Million | €17.20 Million | 0.289x | +108.83% |
| 2023-12-31 | €83.80 Million | €11.60 Million | 0.138x | +69.21% |
| 2022-12-31 | €81.90 Million | €6.70 Million | 0.082x | +290.34% |
| 2021-12-31 | €66.80 Million | €1.40 Million | 0.021x | +105.80% |
| 2020-12-31 | €66.10 Million | €-23.90 Million | -0.362x | -22.16% |
| 2019-12-31 | €84.80 Million | €-25.10 Million | -0.296x | +8.21% |
| 2018-12-31 | €125.90 Million | €-40.60 Million | -0.322x | -25.86% |
| 2017-12-31 | €224.80 Million | €-57.60 Million | -0.256x | -26.85% |
| 2016-12-31 | €280.70 Million | €-56.70 Million | -0.202x | -48.31% |
| 2015-12-31 | €409.70 Million | €-55.80 Million | -0.136x | -- |
About Circassia Group Plc
NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. It offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of Fractional Exhaled N… Read more